SEATTLE (19 July 2026) – ID Genomics, SPC announced today that it has completed its first Pre-Submission meeting with the Food and Drug Administration regarding the CLoNeT E. coli Assay for Urinary Tract Infections (UTIs).
“We continue to make significant progress on our development plans for the CLoNeT E. coli Assay,” said Linda Zuckerman, Ph.D., President and CEO. “This distinctive product will detect the presence of E. coli, ‘fingerprint’ or identify the clonal family involved, and provide a map of antibiotic resistance. Our ultimate aim is to help physicians choose the best antibiotic for UTIs, as well as other infections, before the patient leaves the office.”
In the United States, UTIs account for roughly eight million physician visits and more than 100,000 hospitalizations each year, with an associated annual cost of $1.6 billion. Half of all women will have at least one UTI by age 35, and about 20% of women aged 18 to 24 experience a UTI annually (Simmering et al, 2017). A 2018 study by Thorpe et al. found that antibiotic resistance added approximately $1,300 to the cost of treating a patient with a bacterial infection, leading to costs to payers of up to $2.2B annually.
This is a significant issue for millions of American women. Growing evidence shows that these infections are increasingly resistant to antibiotics, turning routine diagnosis and treatment into situations that lead to more hospitalizations, more serious illnesses, and prolonged discomfort.
About ID Genomics, SPC
ID Genomics, SPC is a leading biotech startup focused on developing cutting-edge molecular diagnostics to detect and map antibiotic resistance. Beyond the CLoNeT E. coli Assay for UTI, the company is developing diagnostic tools for Staphylococcus aureus, Klebsiella pneumoniae, and other pathogenic bacteria. Its BactNet database contains over 31,000 bacterial strains, including more than 10,000 that have been ‘fingerprinted’ into clonal families of antibiotic resistance.
Safe Harbor Disclosure
This news release may contain ‘forward-looking statements’ as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties and are based on the current expectations, views, and beliefs of ID Genomics, SPC as of the date of this release; they should not be relied upon as reflecting the company’s expectations, views, and beliefs at any later date. ID Genomics, SPC disclaims any intention or obligation to update any forward-looking statements, whether due to new information, future events, or otherwise.
